Hassan Maishera
TL;DR
-
Canary Capital has launched the Canary Staked INJ ETF, trading on the Nasdaq under the ticker INJC, offering investors exposure to Injective's native cryptocurrency.
-
The ETF will participate in Injective's proof-of-stake validation process, with net staking rewards reflected in the fund's net asset value.
-
Injective has tokenized over $1 billion in assets, processed more than 3.13 billion transactions, and burned over 7.27 million INJ through its token buyback mechanism.
Canary Capital has launched the Canary Staked INJ ETF on the Nasdaq, giving traditional investors a new way to gain exposure to Injective (INJ) through regulated brokerage accounts.
The exchange-traded fund, trading under the ticker INJC, is designed to track the value of Injective's native token while participating in the blockchain's staking process.
Today, INJ just made history. $INJC, the first U.S. ETF for $INJ, is now live on @Nasdaq with staking built in. A new era of Injective begins now 🧵 https://t.co/hBOff3BtKQ
— Injective 🥷 (@injective) November 5, 2026
Unlike conventional cryptocurrency investment products that primarily hold their underlying assets, the Canary fund seeks to generate additional INJ through proof-of-stake validation.
Net staking rewards will be incorporated into the ETF's net asset value, potentially providing an additional source of returns alongside changes in the token's market price.
The launch coincided with a more than 5% increase in INJ on Thursday, as attention turned toward the blockchain's growing presence in institutional finance and tokenized assets.
Canary Capital Introduces Staked INJ ETF on Nasdaq
Canary Capital's new ETF expands the range of cryptocurrency investment products available through traditional financial markets.
The Canary Staked INJ ETF allows investors to obtain exposure to INJ without directly purchasing the token through a cryptocurrency exchange or managing a digital wallet.
Instead, investors can access the asset through conventional brokerage accounts using the ticker INJC.
The fund also introduces a staking component, distinguishing it from investment vehicles that simply hold digital assets.
According to Canary Capital, the ETF will participate in Injective's proof-of-stake validation process and seek to earn additional INJ. The net rewards generated through this process will be reflected in the fund's net asset value.
Canary Capital CEO Steven McClurg described Injective as a blockchain developed specifically for financial applications.
He argued that investors are increasingly exploring opportunities beyond Bitcoin and Ethereum, particularly in networks focused on trading, tokenization, and financial infrastructure.
The ETF launch reflects that investment thesis by offering exposure to a blockchain designed around onchain financial services.
Injective's SEC-Registered Transfer Agent Supports Institutional Expansion
Injective has also been expanding its presence in regulated financial infrastructure. In August, Injective Institutional Services, an affiliate of the blockchain ecosystem, became a transfer agent registered with the US Securities and Exchange Commission.
Transfer agents perform administrative functions related to securities ownership records and transactions.
These responsibilities can include maintaining shareholder records and processing changes in ownership.
The registration represents an important step in Injective's broader tokenization strategy. It could support efforts to connect blockchain-based asset infrastructure with established financial market processes.
Canary Capital is not the only investment firm pursuing an ETF tied to Injective. Two other proposed products are currently associated with INJ.
The first is the 21Shares Injective ETF. The second is the REX-Osprey INJ Staking ETF. Both proposals indicate that asset managers are exploring investment products linked to blockchain networks beyond the largest cryptocurrencies.
The presence of multiple filings may also suggest expectations of investor interest in Injective-related exposure.
